Patents by Inventor Sinclair Cooper

Sinclair Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230374542
    Abstract: Disclosed herein are various optimized nucleic acids encoding the fukutin-related protein (FKRP). Recombinant vectors comprising the optimized nucleic acid (e.g. operatively linked to a muscle specific promoter), such as recombinant adeno-associated virus vectors, for expressing the protein (e.g. in skeletal and cardiac muscle), and therapeutic compositions contains the vectors are also disclosed. Therapeutic methods of administration of the vectors to a subject for the treatment of a subject with a dystroglycanopathy disorder (e.g., limb-girdle muscular dystrophy 2I) are also disclosed.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 23, 2023
    Applicants: Asklepios BioPharmaceutical, Inc., The University of North Carolina at Chapel Hill
    Inventors: Martin K. Childers, Jorge Omar Yanez-Cuna, Juan Manuel Iglesias Gonzalez, Sinclair Cooper, Antonia Evripioti, Michael L. Roberts, Anna Tretiakova, Lester Suarez, Anh Nguyen, SiewHui Low, Xiao Xiao
  • Publication number: 20230340528
    Abstract: The present invention relates to methods of administration of rAAV vectors in a single administration method comprising a series of sub-administrations of sub-doses of rAAV vectors. The present invention also relates to rAAV vectors comprising cardiac-specific promoters, cardiac-cell specific promoters, multi-cell cardiac specific promoters, and elements thereof. The invention also relates to rAAV vectors, pharmaceutical compositions and uses thereof in methods for treating cardiovascular disease, heart diseases and heart failure in subjects in need thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: October 26, 2023
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL INC.
    Inventors: Michael W. O’CALLAGHAN, Michael L. ROBERTS, Jorg Omar YANEZ-CUNA, Juan Manuel IGLESIAS GONZALEZ, Antonia EVRIPIOTI, Sinclair COOPER, Ferzin SETHNA, Roger HAJJAR, Anna TRETIAKOVA
  • Publication number: 20230321279
    Abstract: The present invention relates to regulatory nucleic acid sequences, in particular NS-specific promoters, cell specific promoters, multi-cell specific promoters, and elements thereof. The invention also relates to expression constructs, vectors, virions, pharmaceutical compositions and cells comprising such promoters and to methods of their use. The regulatory nucleic acid sequences are of particular utility for gene therapy applications.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 12, 2023
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventors: Anne BRAAE, Juan Manuel Iglesias, Michael L. Roberts, Sinclair Cooper
  • Publication number: 20230233710
    Abstract: The present invention relates to regulatory nucleic acid sequences, in particular muscle-specific promoters, elements thereof, and other such nucleic acid sequences, that are capable of enhancing muscle-specific expression of genes. The invention also relates to expression constructs, vectors and cells comprising such muscle-specific regulatory nucleic acid sequences, and to methods of their use. The regulatory nucleic acid sequences are of particular utility for gene therapy applications, but also find utility in other areas such as bioprocessing and biotechnology.
    Type: Application
    Filed: December 24, 2020
    Publication date: July 27, 2023
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventors: Jorge Omar Yanez-Cuna, Juan Manuel Iglesias, Sinclair Cooper, Katie Baker, Polyxeni Katsoupi, Rinku Rajan, Ileana Guerrini, Antonia Evripioti, Kira Mourao, Michael L. Roberts
  • Publication number: 20230143758
    Abstract: The present invention relates to regulatory nucleic acid sequences, in particular CNS—specific promoters, and elements thereof. The invention also relates to expression constructs, vectors, virions, pharmaceutical compositions and cells comprising such promoters and to methods of their use. The regulatory nucleic acid sequences are of particular utility for gene therapy applications.
    Type: Application
    Filed: April 19, 2021
    Publication date: May 11, 2023
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventors: Tony Oosterveen, Anne Braae, Sinclair Cooper, Juan Manuel Iglesias, Michael L. Roberts